What's the reality for CDK4/6 inhibitors: Clinical trials or real-world evidence?
- PMID: 36760039
- DOI: 10.1002/cncr.34672
What's the reality for CDK4/6 inhibitors: Clinical trials or real-world evidence?
Keywords: CDK4/6 inhibitor; breast cancer; geriatric oncology; metastatic; real world evidence.
Comment on
-
Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study.Cancer. 2023 Apr 1;129(7):1051-1063. doi: 10.1002/cncr.34675. Epub 2023 Feb 9. Cancer. 2023. PMID: 36760031
References
REFERENCES
-
- Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020;395(10226):817-827. doi:10.1016/S0140-6736(20)30165-3
-
- Goyal. Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER Medicare population-based study. Cancer. Published online 2022.
-
- Bradley EH, McGraw SA, Curry L, et al. Expanding the Andersen model: the role of psychosocial factors in long-term care use. Health Serv Res. 2002;37(5):1221-1242. doi:10.1111/1475-6773.01053
-
- Bellera CA, Rainfray M, Mathoulin-Pélissier S, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012;23(8):2166-2172. doi:10.1093/ANNONC/MDR587
-
- Alcaraz KI, Wiedt TL, Daniels EC, Yabroff KR, Guerra CE, Wender RC. Understanding and addressing social determinants to advance cancer health equity in the United States: a blueprint for practice, research, and policy. CA Cancer J Clin. 2020;70(1):31-46. doi:10.3322/CAAC.21586
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical